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The heat shock protein (HSP) Hsp90 is known to chaperone cytosolic peptides for MHC
class I (MHCI)-restricted antigen presentation toT lymphocytes. We now demonstrate a
role for Hsp90 activity in presentation of antigens on MHCII. Treatment of mouse
antigen-presenting cells (APC) with the pharmacological Hsp90 inhibitor, geldanamy-
cin, inhibited MHCII-mediated presentation of endocytosed and cytosolic proteins as
well as synthetic peptides to specific T cells. Ectopic expression of human Hsp90 in APC
enhanced MHCII-mediated antigen presentation. Further, pharmacological Hsp90
inhibition reduced, while retroviral Hsp90 overexpression enhanced, the levels of stable
compact MHCII heterodimers correlating with the antigen presentation phenotype.
Pharmacological inhibition of Hsp90 activity in IFN-c-treated APC resulted in severe
abrogation of MHCII-restricted presentation of cytosolic antigen, but only partially
inhibited exogenous antigen presentation. Our data suggest a major role for Hsp90
activity in MHCII-mediated antigen presentation pathways, and implicate IFN-c-
inducible Hsp90-independent mechanisms.
Introduction
Themolecular chaperone Hsp90 is critical to amultitude
of cellular functions [1, 2]. Hsp90 can act as a general
chaperone preventing the aggregation of unfolded
polypeptides [3, 4] and, in concert with chaperones
of the Hsp70 family and other co-chaperones, is
intimately associated to protein degradation in the cell.
Hsp90 has been described as the cellular target of
benzoquinoid ansamycin drugs such as geldanamycin
and herbimycin [5] shown to prevent Hsp90-mediated
refolding of a variety of cellular proteins, directing them
for degradation by the proteasome. X-ray crystallo-
graphic evidence suggests that geldanamycin serves as
an ATP/ADP mimetic and binds the amino-terminal
pocket of Hsp90 [6], inhibiting ATPase activity and
consequently ATP-dependent peptide release [7]. Asso-
ciation of Hsp90 with the 20S proteasome has been
shown to influence proteasomal enzymatic activity [8].
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Loading of peptides generated in APC such as
macrophages and B lymphocytes on MHC molecules is
essential for recognition by T lymphocytes. HSP-
chaperoned peptides are loaded on to MHC class I
(MHCI) with much greater efficiency than free peptides
in the cytosol [9], which may otherwise be prone to
cytoplasmic proteolysis in the absence of chaperone
association. Recent evidence demonstrates the role of
HSP in cross priming of CD8 T cells, which recognize
their target peptides bound to MHCI [10].
While cytosolically generated ligands are loaded on
MHCI in the endoplasmic reticulum [11], MHC class II
(MHCII) molecules bind to peptides in endolysosomal
compartments, which are then presented to CD4 T cells.
Assembled MHCII ab heterodimers traverse from the ER
to the late endocytic compartments bound by the
invariant chain (Ii) [12, 13]. Endolysosomal cysteine
proteinases or cathepsins [14] mediate steps of Ii
degradation in APC leaving a short MHCII-associated
Ii peptide, CLIP, protecting the peptide-binding groove.
The H-2 M molecule facilitates CLIP removal [15],
rendering the MHCII molecule capable of peptide
binding and stable MHCII-peptide complexes transit
to the plasma membrane for T cell recognition.
Peptides from cytoplasmic antigens have also been
shown to gain access to the MHCII pathway for
presentation [16–20]. Ligand generation through alter-
nate pathways complements conventional processing
events and widens the spectrum of epitopes made
available for recognition by CD4 Tcells [19, 20]. We have
previously reported that processing events generating
MHCII-binding peptides in the cytosol are distinct from
those generating peptides in the endocytic pathway and
that endogenous processing is reliant on proteasomal
function [18]. Our data have further demonstrated that
endolysosomal vesicular compartments are a point of
convergence for peptides generated both by endolyso-
somal as well as by cytosolic processing events [21].
Distinct proteolytic mechanisms operative in different
APC subpopulations and in different subcellular loca-
tions may create quantitative and qualitative alterations
in the nature of peptides complexed to MHC and as a
result the T cell response [22]. Putative peptide ligands
are constantly faced with the constitutive proteolytic
machinery of the cell that in the process of epitope
generation could incur epitope destruction. Peptide
epitope precursors have been found to be associated in
vivowith heat shock proteins such Hsp70, Hsp90 and the
ER chaperone, gp96, providing a mechanism for HSP to
modulate antigen presentation [23].
Most studies thus far have focused on the interactive
role of chaperones with components of the MHCI
pathway [24, 25]. Experimental studies also provide
evidence for HSP-peptide complexes in facilitating in
vivo presentation of MHCII-restricted epitopes [25–27].
As HSP proteins associate in vivo with a wide range of
intracellular peptides generated in varied sub cellular
locations, we asked whether the presentation of
endosomally or cytosolically generated MHCII ligand
peptides is modulated byHsp90. Our data demonstrate a
requirement for Hsp90 in MHCII-mediated presentation
of peptides from all sources. We suggest that Hsp90 may
modulate antigen presentation in part by effects on
stable MHCII heterodimer formation or persistence.
Further, the requirement for Hsp90 functions in antigen
presentation differs between cell lineages for MHCI and
can be partially bypassed by IFN-c activation of APC for
MHCII.
Results
General remarks
The finding that a class of ansamycin antibiotics such as
geldanamycin specifically bind Hsp90 [5–7] allowed us
to begin addressing the specific role of Hsp90 in antigen
presentation pathways.
Geldanamycin inhibits MHCII-restricted
presentation by antigen-loaded B cell and
macrophage APC
We studied the presentation of a well-characterized
APC-endogenous peptide for its sensitivity to geldana-
mycin. Processing of the extracytoplasmic region of the
MHCII polypeptide I-Ea (H2-Ea) yields an epitope, EapL
(aa 52–68), which binds to and is presented in the
context of H2-Ab. APC from mouse strains such as
B10.A(3R) constitutively express the Eap-H2-Ab com-
plex on their surface [28]. We used peritoneal macro-
phages from B10.A(3R) mice to study the effects of
geldanamycin on endogenous presentation of EapL-H2-
Ab to the Tcell hybridoma 1H3.1, which recognizes both
the peptide from derived from exogenous pulsed protein
sources, EapS (aa 52–66), as well as the constitutive
endogenous derived long peptide, EapL (aa 52–68), in
the context of H2-Ab. Geldanamycin completely in-
hibited presentation of endogenous EapL to 1H3.1
(Fig. 1A). Further, MHCII-restricted presentation of
exogenous OVA by the same APC to the Tcell hybridoma
13.8, was similarly abolished (Fig. 1B). Similar results
were obtained when the B cell line LB27.4, which also
expresses H2-Ea constitutively, was used as APC (data
not shown).
Recent studies have demonstrated the effect of
bacterially derived HSP on the exogenous antigen-
processing pathway for MHCII [29]. Exogenous antigen
entry to the MHCII-mediated presentation pathway
occurs via endocytosis or fluid phase uptake by
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pinocytosis and contributes to the better-characterized
conventional pathway for internalization and presenta-
tion of extracellular ligands on MHCII. As a comple-
mentary approach for antigen delivery directly to the
cytosol, we have made use of osmotic lysis of pinosomes,
which has been previously shown to introduce exogen-
ous antigens into proteasome-dependent pathways of
antigen presentation [18, 30]. This methodology allows
for delivery and parallel assessment of equivalent
quantities of the same protein in distinct subcellular
locations. Using such a system, we looked at effects of
geldanamycin on MHCII-restricted presentation of
endocytosed versus cytosolically introduced protein.
Figure 1. Geldanamycin inhibits MHCII-restricted presentation of endogenous and exogenous proteins. (A, B) Peritoneal
macrophages elicited from B10.A(3R) mice, treated for 16 h with either geldanamycin (GA; 5 lM) or vehicle alone, were pulsed
exogenously with OVA (3 mg/mL) in the medium for 3 h in the presence or absence of GA, fixed, washed and assessed for either
endogenous EapL presentation to the 1H3.1 T cell line (A), or exogenous OVA presentation to the 13.8 T cell line (B). (C–E) Peritoneal
macrophages elicited from C57BL/6 mice, treated for 1 h with titrating concentrations of GA, were loaded with OVA (10 mg/mL)
either exogenously (C) or cytosolically (D, E) as indicated. The cellswere incubated for an additional 3 h in the presence or absence
of GA, washed, fixed and used as APC for presentation to 13.8 (C, D) or B3Z (E) T cells as indicated. Unpulsed APC were used as
negative controls. (F–H) Resting peritoneal macrophages from C57BL/6 mice (F), BMC-2 cells (G) or LB27.4 cells (H) treated for 1 h
with either 7.5 lMGA or vehicle, were loaded cytosolically with OVA (10 mg/mL). The cells were incubated for an additional 3 h in
thepresence or absence of GA,washed, fixed and used asAPC for presentation to B3ZT cells as indicated. UnpulsedAPCwere used
as negative controls. In all panels, the IL-2 (1H3.1) or b-galactosidase (13.8 and B3Z) levels induced are indicated, and all data are
representative of at least three independent experiments. Error bars represent mean  standard deviation of triplicate wells.
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Peritoneal macrophages were pulsed with OVA either
through the exogenous pathway by pinocytosis or
directed to the cytosol by osmotic lysis of pinosomes.
Mock-loaded or antigen-loaded macrophages were used
as APC. While APC loaded with antigen through either
mode of delivery presented OVA efficiently on MHCII to
13.8 cells, presentation was inhibited in a dose-
dependent manner by geldanamycin (Fig. 1C and D).
We assessed treated APC by trypan blue exclusion and
found no adverse effects of geldanamycin on cell
viability. Since a concentration of 7.5 lM geldanamycin
was found to effectively inhibit MHCII-restricted antigen
presentation with no adverse effects on cell viability, we
used this concentration for treatment of APC prior to
and during antigen loading in all further assays.
Interestingly, the same macrophage APC showed no
significant inhibition when assessed for presentation of
cytosolically loaded OVA to the Kb-restricted T cell line,
B3Z (Fig. 1E). Since these experiments used thiogly-
collate-activated peritoneal macrophages as APC, it was
imperative to ascertain the contribution of inherent
activation status of primed APC to the observed pattern
of presentation. To address this, we used either non-
activated, peritoneal resident cell-derived macrophages
(Fig. 1F), or the H-2b BMC-2 monocytic cell line
(Fig. 1G) as APC. In these monocytic APC, too, MHCI-
restricted presentation of cytosolic OVA was not
inhibited by geldanamycin (Fig. 1F and G). These results
indicate that the geldanamycin-insensitivity of cytosolic
OVA presentation on MHCI is independent of matura-
tion status of the macrophage APC. While ruling out the
possible toxic effects of the drug, these results present an
apparent discordance with earlier data that support a
role for Hsp90 function in MHCI-restricted antigen
presentation [31]. A potential explanation came from
the observation that MHCI-restricted cytosolic OVA
presentation by splenic mixed APC populations was
sensitive to geldanamycin (data not shown), indicating
possible lineage-specificity in the Hsp90 requirement for
the MHCI presentation pathway. We directly addressed
this possibility by assessing the geldanamycin sensitivity
of the presentation of cytosolically delivered OVA in the
B cell line LB27.4. Unlike the monocytic APC, MHCI-
restricted cytosolic OVA presentation by LB27.4 was
geldanamycin sensitive (Fig. 1H).
Together, the above data show that while MHCII-
restricted presentation of both exogenous and cytoso-
lically delivered antigen as well as of constitutively
expressed endogenous antigen is uniformly geldanamy-
cin sensitive, there exist APC lineage-specific differences
in the effects of geldanamycin on the MHCI-mediated
antigen presentation pathway.
Peptide presentation on MHCII but not MHCI is
geldanamycin sensitive
Inhibition of antigen presentation could either be due to
effects on peptide generation or peptide loading. To
further understand the step at which geldanamycin
intercepts the MHCII pathway we looked at effects on
presentation of synthetic peptides. Exogenous proces-
sing of the H2-Ea protein generates the short peptide
EapS (aa 52–66), while constitutive processing of the
endogenous protein leads to the generation of the long
peptide EapL (aa 52–68) for presentation onH2-Ab [28].
Synthetic EapL or EapS were directly introduced into the
cytosol or pulsed exogenously on macrophage APC pre-
incubated with geldanamycin for 1 h prior to peptide
loading. Presentation of both peptides on MHCII was
completely blocked by geldanamycin (Fig. 2A and B).
Under similar conditions of treatment, exogenous
presentation of the Kb-restricted OVA-derived peptide
SIINFEKL to the MHCI-restricted T cell line B3Z was
unaltered (Fig. 2C). Since MHCI-restricted antigen
presentation of both native antigen as well as peptide
in macrophage APC appeared to be geldanamycin
resistant, we also examined the geldanamycin sensitivity
of SIINFEKL presentation by the B cell line LB27.4,
wherein the MHCI-mediated OVA presentation is
geldanamycin sensitive. SIINFEKL presentation by these
B cell APC was found unaltered by geldanamycin
treatment (Fig. 2D), indicating that the inhibitory
effects of geldanamycin on peptide presentation were
specific to MHCII. The difference in pattern of
geldanamycin sensitivity of peptide loading on MHCI
versus MHCII was further assessed by looking into the
requirement of metabolically active APC for EapS
presentation using the following three approaches.
First, paraformaldehyde fixation of APC prior to peptide
pulse abrogated EapS presentation (Fig. 2E), suggesting
that unlike MHCI-restricted presentation of SIINFEKL
peptide, EapS presentation was not mediated by peptide
loading at the cell surface and the process required
metabolically active APC. Secondly, pretreatment of APC
with an inhibitor of actin polymerization, cytochalasin B
[32], resulted in a complete loss of EapS presentation
(Fig. 2F), again suggesting peptide internalization is a
pre-requisite for EapS presentation. Thirdly, treatment
of APC with the vacuolar ATPase inhibitor, concanamy-
cin A [33] that prevents endosomal acidification also
abrogated EapS presentation (Fig. 2E). Thus, EapS
presentation depends on internalization and requires
intact endosomal function. In all these experiments, no
discernable effects on presentation of the SIINFEKL
peptide (Fig. 2G and data not shown) were observed.
These results indicate that geldanamycin-mediated
inhibition of peptide presentation is attributable at least
in part to effects on endosomal post-processing peptide
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loading on MHCII rather than on peptide exchange at
the cell surface.
Overexpression of Hsp90 enhances antigen
presentation
The effects of geldanamycin are reported to be mediated
through its action as an Hsp90-specific inhibitor. The
Hsp90 family includes the ER-resident glucose-regu-
lated protein (Grp94) and the mitochondrial tumor
necrosis factor receptor-associated protein (TRAP1)
along with Hsp90 [34, 35]. To correlate the effects of
geldanamycin with Hsp90, we made use of a comple-
mentary approach. Ectopic expression of either Hsp90
or enhanced green fluorescent protein (eGFP) was
achieved in the H2-Ab monocytic cell line BMC-2 as well
as in the B cell line LB27.4 by retroviral transduction.
The transduced cells were grown under selecting
Figure 2. Geldanamycin inhibits MHCII-restricted peptide presentation. (A–C) Peritoneal macrophage APC elicited from C57BL/6
mice, or LB27.4 cells (D), treatedwith either GA (7.5 lM) or vehicle alonewere pulsed exogenously (exo) or cytosolically (cyto) with
EapL (A) or EapS (B), or with exogenous SIINFEKL peptide (C, D), and responses of the MHCII-restricted T cell line 1H3.1 (A, B) or of
the MHCI-restricted line B3Z (C, D) were tested. (E, F) C57BL/6macrophage APCwere either pre-fixedwith 0.1% paraformaldehyde
(E; 'pre-fix') or treatedwith the indicated concentrations of concanamycin A, CA, (E) or were treated (F) with cytochalasin B, cyto B,
prior to EapS pulsing and use for assessing the responses of the 1H3.1 T cell line. Cytochalasin B-treatedAPCwere also pulsedwith
the SIINFEKL peptide and assessed for the ability to stimulate the MHCI-restricted B3Z T cell line (G). In all cases with inhibitor
treatment, APC pretreated with vehicle alone were pulsed with the relevant peptide and used as controls. The data shown are
representative of three to four independent experiments and error bars represent mean  standard deviation of triplicate wells.
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conditions, and the resultant cell lines were used as APC
for antigen-presentation assays.
Hsp90 transduction resulted in an increment in
cellular Hsp90 expression as evidenced by FACS analysis
(Fig. 3A), while total as well as surface MHCII levels
remained relatively unaltered (Fig. 3B, C). We next
assessed the antigen presentation ability of Hsp90-
overexpressing cells and found that MHCII-restricted
Figure 3. Ectopic expression of Hsp90 enhances MHCII-restricted antigen presentation. (A–C) Human Hsp90 was retrovirally
transduced into the mouse B cell line LB27.4 and puromycin-selected cell populations tested for cellular expression of Hsp90 (A)
and MHCII (B, C) in unpermeabilized for surface levels (B) and post-permeabilization for total levels on cells (C). The shaded
histogramdepicts the isotype control. (D) Untransduced control or retrovirally (Hsp90 or eGFP-RV) transduced BMC-2 cells selected
for expression of human Hsp90 or eGFP werewashed extensively and tested for presentation of pulsed exogenous OVA in graded
doses to theMHCII-restricted T hybridoma 13.8. (E–G) Retrovirally transduced LB27.4 selected for carriage of human Hsp90 (Hsp90
RV) or eGFP (eGFP RV)werewashed extensively and tested for endogenously derived EapL presentation to 1H3.1 (E), presentation of
pulsed exogenous OVA (5 mg/mL) to the MHCII-restricted T hybridoma 13.8 (F) or presentation of exogenously pulsed SIINFEKL
peptide (1 lg/mL) to the MHCI-restricted T cell line B3Z (G). (H) Control (eGFP) or Hsp90-expressing LB27.4 cells selected on
puromycin were washed extensively and treated with 5 lM GA for 16 h, and tested for endogenous presentation of EapL to the T
cell line 1H3.1. All data shown are representative of at least three independent experiments. Error bars representmean standard
deviation of triplicate wells.
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presentation of exogenous OVA by BMC-2 cells over-
expressing Hsp90 was greatly enhanced as compared to
untransduced or eGFP-transduced controls (Fig. 3D). An
enhancement of endogenous H2-Ea-derived peptide
presentation on MHCII was similarly observed in the B
cell line LB27.4 overexpressing Hsp90 (Fig. 3E). Ad-
ditionally, when these APC were pulsed with exogenous
OVA, MHCII-restricted OVA presentation was also
greatly enhanced (Fig. 3F). APC overexpressing Hsp90
however had unchanged potential to present the MHCI-
restricted SIINFEKL peptide (Fig. 3G). Unaltered
patterns of presentation in eGFP-transduced cells
provided an appropriate control for possible incidental
effects of retroviral transduction. In order to confirm
further that the enhanced MHCII-restricted antigen
presentation seen in Hsp90-transduced cells was
attributable specifically to Hsp90 and not due to the
inadvertent selection of an improved presentation
phenotype, we examined the geldanamycin sensitivity
of these Hsp90 overexpressing cells. Geldanamycin
treatment resulted in complete loss of endogenous EapL
presentation on MHCII in Hsp90-overexpressing LB27.4
(Fig. 3I). Taken together, the results suggest that Hsp90
is the geldanamycin target instrumental in modulating
MHCII-restricted antigen presentation.
Hsp90 affects formation of SDS-stable MHCII
dimers
Results described thus far are suggestive of a role for
Hsp90 in endosomal peptide loading on MHCII. An
outcome of successful peptide loading is the generation
of SDS-stable MHCII heterodimers [36, 37]. Surface and
total cellular MHCII levels as observed in unpermeabi-
lized and permeabilized APC, respectively, were found
to remain unaffected by Hsp90 overexpression (Fig. 3C
and D). Therefore, the enhanced presentation cannot be
attributed to simple alterations in MHCII levels. The
observed differences in MHCII presentation on gelda-
namycin treatment may thus indicate a possible
endosomal function for Hsp90 that, by supporting
efficient peptide loading, would modulate the formation
and/or persistence of SDS-stable MHCII heterodimers.
To assess this possibility, whole-cell lysates from Hsp90-
transduced or eGFP-transduced LB27.4 were subjected
to non-reducing SDS-PAGE followed by Western blot
analysis using the H2-Ab-specific mAb, Y3P.
LB 27.4 cells overexpressing Hsp90 revealed en-
hanced levels of SDS-stable MHCII heterodimers
(Fig. 4A), while total MHCII levels were unaltered
(Fig. 4B). The H2-Ab-specific mAb Y3P does not
recognize isolated MHCII polypeptides and therefore
the SDS-unstable components of H2-Ab would not be
visualized in such a Western blot analysis. Enhanced
levels of SDS-stable MHCII heterodimers thus correlate
with enhanced antigen presentation on MHCII
(Fig. 3D–F). We also assessed the levels of SDS-stable
MHCII dimers in geldanamycin-treated macrophage
APC, which show an inhibition of MHCII-restricted
antigen presentation. Treatment of C57BL/6 peritoneal
macrophages with graded doses of geldanamycin prior
to Western blot analysis revealed a reduction of SDS-
stable MHCII heterodimers in a graded dose-response
manner (Fig. 4C). However, both Hsp90 expression and
total MHCII levels remained unchanged at all concen-
trations tested (Fig. 4D).
Thus, the loss or enhancement in antigen presenta-
tion on MHCII in geldanamycin-treated or Hsp90-
overexpressing APC, respectively, correlates well with
the generation of SDS-stable MHCII heterodimers. The
unaltered surface and cellular MHCII levels rule out the
Figure 4. Hsp90 enhances SDS-stable MHCII heterodimer
levels. (A) Whole-cell lysates from Hsp90-overexpressing
LB27.4 cells were resolved on non-reducing SDS-PAGE and
Western blotted with either the anti-I-Ab mAb, Y-3P or an anti-
actin antibody. The lanes indicate lysates from untransduced
(1), control eGFP-retrovirus-transduced (2) and Hsp90 retro-
virus-transduced (3) LB27.4 cells. (B) Surface MHCII levels in
LB27.4 cells transducedwith a control retrovirus (solid lines) or
the Hsp90-bearing retrovirus (dotted lines). Shaded histogram
represents isotype control. (C) Western blot analyses of LB27.4
whole-cell lysates left untreated (lane 1) or treatedwith various
concentrations of geldanamycin (lanes 2–5; 10, 7.5, 5 and
2.5 lM, respectively) simultaneously probed with an anti-
Hsp90 mAb and the anti-I-Ab mAb Y3P are shown. (D) Surface
levels ofMHCII are shown corresponding to lanes 1 to 5 in panel
(C). All data shown are representative of two to four
independent experiments.
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possible effects of geldanamycin in MHCII biosynthesis.
It seems plausible that the surface MHCII molecules in
geldanamycin-treated APC may either be 'floppy' dimers
that are empty or CLIP-bound [38].
Effects of geldanamycin on MHCII-restricted
antigenpresentationinactivatedmacrophageAPC
Antigen presentation pathways for both MHCI and
MHCII are affected by IFN-c, which is known to induce
MHC levels and cytosolic proteolytic machinery [39] as
well as modulate endolysosomal protease activity [40,
41]. To examine the effect of IFN-c activation on the role
of Hsp90 in antigen presentation, we used IFN-c-
stimulated B10.A(3R)-derived macrophages. As noted
above, APC from this recombinant mouse strain
constitutively express the H2-Ea protein as well as the
H2-Ab restricting element and therefore provide a
system to assess effects on both endogenous and
exogenous antigen presentation on MHCII by similarly
treated APC. IFN-c-activated APC revealed an increase
in the surface levels of MHCII, which is unaffected by
Figure 5. Geldanamycin affects MHCII-restricted antigen presentation by activatedmacrophage APC. (A) Peritoneal macrophages
elicited from B10.A(3R) mice were rested overnight prior to stimulation with IFN-c (gray lines) or left unstimulated (black lines).
Both sets were either treated with GA (dotted lines) or left untreated (solid lines), were stained for surface MHCII expression and
assessed by flow cytometry. (B, C) Surface levels of CD80 (B) and CD86 (C) expression on B10.A(3R) peritoneal macrophages either
treated with GA (dotted lines) or left untreated (solid lines). (D, E) B10.A(3R) peritoneal macrophages as in panel (A), were either
stimulatedwith IFN-c or left unstimulated (control) for 48 h. During the last 16 h, the cells were treated either with geldanamycin
(5 lM) or with vehicle alone. All cell groups were pulsed with 3 mg/mL OVA for the last 3 h of culture prior to fixation and use as
APC for presentation to 1H3.1 (D) or 13.8 (E) T cell lines. (F, G) B10.A(3R) peritonealmacrophageswere either stimulatedwith LPS or
left unstimulated (control) for 48 h. During the last 16 h, the cells were treated either with geldanamycin (5 lM) or with vehicle
alone. All cell groupswere pulsedwith 3 mg/mL OVA for the last 3 h of culture prior to fixation and use as APC for presentation to
1H3.1 (F) or 13.8 (G) T cell lines. All data shown are representative of two to three independent experiments.
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geldanamycin treatment (Fig. 5A). To exclude possible
confounding influences of geldanamycin on other cell
surface molecules, the expression of costimulatory
molecules CD80 and CD86 was examined. As shown,
the expression of CD80 (Fig. 5B) and CD86 (Fig. 5C) on
similarly treated macrophage APC was unaffected by
geldanamycin treatment.
MHCII-mediated presentation of endogenous H2-Ea
as well as of exogenously delivered OVA were enhanced
following IFN-c-stimulation (Fig. 5D and E). Treatment
with geldanamycin resulted in almost complete
abrogation of MHCII-restricted endogenous H2-Ea
presentation on both control and IFN-c-stimulated
macrophages (Fig. 5D). When these APC were pulsed
exogenously with OVA during the last 3 h of incubation
and MHCII-restricted OVA presentation assessed, we
found that exogenous OVA presentation by resting APC
was almost completely inhibited. In contrast, IFN-c-
activated APC retained a substantial capability to
present exogenous OVA on MHCII even when treated
with geldanamycin (Fig. 5E). Thus, in IFN-c-activated
APC, geldanamycin treatment led to a reduction of
endogenous H2-Ea presentation by a dose-response
curve shift of over 30-fold, while the reduction of
exogenous OVA presentation by the same APC was only
about 10-fold. These results indicate that a component
of MHCII-restricted antigen presentation of exogenous
antigen in IFN-c-activated macrophage APC may be
differentially dependent on Hsp90, while this is not the
case for presentation of endogenous antigen. We
observed no alteration of Hsp90 expression in activated
APC (data not shown).
We further looked at the effects of APC activation by
the microbial byproduct LPS on the Hsp90-dependence
of MHCII-restricted presentation. Similar to the effects
of IFN-c, macrophage APC activated with LPS showed
enhanced levels of surface MHCII that was unaltered by
geldanamycin treatment (data not shown). Endogenous
antigen presentation was found to remain sensitive to
inhibition by geldanamycin (Fig. 5F). Interestingly, we
found that, unlike the situation with IFN-c treatment,
the exogenous pathway of MHCII-mediated presenta-
tion also remained completely sensitive to geldanamycin
in LPS-activated APC (Fig. 5G). These data suggest that
the geldanamycin-insensitivity of the exogenous MHCII
presentation pathway induced by IFN-c is specific and is
not mimicked by other pathways of APC activation.
Discussion
Recognition of a broad spectrum of epitopes is crucial to
the initiation of effective T cell responses and the ability
of the immune system to cope with disparate site(s) of
antigen access. We have been investigating pathways
leading to MHCII-restricted presentation of ligands
generated from endogenous antigen, conventionally
recognized for presentation by the MHCI pathway. Data
from others and our group envisage a dichotomy in the
sub cellular location of antigens sampled and recognized
by the MHCII presentation pathway [16–21]. Depen-
dence on chaperone protection is well established for
putative MHCI ligands and the ability of HSP such as
Hsp70 and ER-Gp96 to co-ordinate binding and release
of intracellular peptides in an ATP-dependent fashion
argues for the notion that peptide ligands for MHCI
binding may not simply diffuse to transporters but may
in fact be chaperoned [10, 42, 43].
Fluid-phase endocytosis allows for antigen access to
the conventional route for processing and presentation
through the MHCII pathway. Analysis of peptides on
MHCII however reveals many MHCII-binding peptides
to be from cellular rather than extracellular protein
sources [44, 45]. We have made use of hyperosmotic
lysis of pinosomes for experimental loading of antigen
into the cytosol [18, 30]. This procedure allows for
antigen delivery directly to the cytosol and enables a
parallel and quantitative comparison of similar protein
amounts delivered to distinct intracellular locations
namely the cytosol versus the conventional endolyso-
somal pathway by isotonic fluid-phase uptake. The
approach for hyperosmotic lysis based delivery of
antigen to the cytosol versus exogenous delivery can
thus be considered representative of biosynthetic and
exogenous routes of antigen delivery. The possible
presentation of residual antigen from unruptured
pinosomes through the classical pathway has been
formally shown not to occur, establishing this distinction
between residual endosomal and truly cytosolic source
of loaded antigen [18].
Based on this background, we attempted in the
present study to examine whether Hsp90 contributed
differentially to MHCII-restricted presentation of cyto-
solic and endosomal proteins. However, our data show
that peptide ligands generated through processing of
both endosomal and cytosolic antigen sources rely on
Hsp90 for optimal presentation. The obtained results are
supported by the analysis of presentation of I-Ea
processing as a physiologically endogenous antigen
presentation system.
Prior data from our group has demonstrated that
while distinct proteolytic mechanisms support the
generation of peptide ligands in the cytosol versus
endosomes, antigenic peptides from both sources bind
MHCII in the LAMP-1-positive endo-lysosomal compart-
ments [21]. The requirement of Hsp90 for the
presentation of both endogenous as well as internalized
antigen presentation suggests two possibilities. Hsp90
may function to chaperone peptides in either subcellular
location up to the point of MHCII association, and/or
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participate in MHCII peptide-loading complex forma-
tion. Since the endolysosomal compartment serves as a
focal point for loading of peptide ligands on MHCII, we
assessed the possible endosomal contribution of Hsp90
to the generation of stable MHCII heterodimers.
Efficient peptide loading favors the formation of stable
MHCII heterodimers resistant to disruption by chao-
tropic agents such as SDS and onward transit of MHCII-
peptide complexes to the cell surface is determined by
stable peptide binding. Enhanced levels of SDS-stable
MHCII heterodimers in cell lines overexpressing Hsp90,
and the dose-dependent inhibitory effect of geldana-
mycin on stable dimer levels, both correlate well with a
functional role for Hsp90 in effective antigen presenta-
tion through the MHCII pathway.
Bearing in mind the role of Hsp90 as a chaperone in
assembly of cellular proteins, it is plausible that
geldanamycin-mediated inhibition of MHCII-restricted
presentation could be due to overall effects on MHCII
folding and assembly. We find that both upon geldana-
mycin treatment and overexpression of Hsp90, the
MHCII expression patterns remain unaltered ruling out
the possibility of direct effects of Hsp90 on the MHCII
biosynthetic pathway as a cause for inhibitory effects of
geldanamycin. Longer incubation with geldanamycin
that completely abrogated both endogenous EapL
presentation and SDS-stable dimer generation did not
alter the MHCII expression patterns in treated cells. It
seems possible that either the surface levels of CLIP
loaded MHCII may be increased in geldanamycin-
treated APC, or that there is increased representation
of floppy dimers of MHCII as has been reported
previously [38]. Furthermore, the absence of any
changes in the CD80 and CD86 expression profiles
excludes any nonspecific effects on stability of cell
surface molecules.
The Hsp90-dependency of stable MHCII dimers on
APC suggests that chaperones like Hsp90 might either
directly associate with floppy dimers and facilitate
formation of peptide associated compact dimers, or
function to chaperone the optimal peptide for binding to
MHCII. Our initial experiments in this regard suggest a
direct association of Hsp90 with MHCII (unpublished
observations). The sensitivity of synthetic EapS peptide
presentation to geldanamycin points out that MHCII-
restricted peptide loading in the endosomal compart-
ments occurs through a process aided by Hsp90.
Interestingly, this effect on peptide presentation is an
MHCII-specific property of Hsp90 in the sense that
presentation of exogenously added MHCI-restricted
peptide is unaffected by Hsp90. A non-exclusive
additional possibility could also be that Hsp90 enhances
the stability of mature peptide-MHC complexes. Thus,
Hsp90 appears to integrate with various aspects of the
MHCII presentation pathway, and its effects on the
peptide loading process may be one of the factors
determining stability of peptide loaded MHCII.
Geldanamycin is reported to adversely affect T cell
activation and IL-2 secretion. The use of paraformalde-
hyde-fixed, inhibitor-treated APC ensures that the
observed effects of geldanamycin are APC-specific and
not due to other effects on T cells. That the observed
inhibitory effects of geldanamycin in our system are
specific to Hsp90 is borne out by retrovirus-mediated
transfer of Hsp90 to APC. Cells overexpressing Hsp90
exhibit a phenotype complementary to that observed
following treatment with geldanamycin. We have ruled
out retroviral transduction as the cause for observed
enhanced antigen presentation phenotype by the use of
control APC transduced with eGFP-carrying retrovirus.
Further, the sensitivity of the phenotype to inhibition by
geldanamycin provides another level of confirmation for
the specific role of Hsp90.
We find that unlike the uniform dependence of the
MHCII-restricted presentation pathway on Hsp90 in
macrophage and B cell lineages, presentation in the
context of MHCI in B cells versus macrophages is distinct
in terms of Hsp90 requirements. A potential explanation
for this lineage-specific effect in which B cells require
Hsp90 for MHCI-restricted presentation while macro-
phages do not, could be related to distinct functional
attributes of immuno-proteasomes in B cells versus
macrophages, although this issue needs to be addressed
in further detail.
Our data reveal a strong dependence of MHCII-
restricted presentation of internalized exogenous anti-
gen on Hsp90 function. This seems intriguing in context
of the cytosolic localization of Hsp90. Although the
precise sub-cellular location of Hsp90 with regard to
MHCII processing compartments is not clearly under-
stood, recent findings report the presence of Hsp90 on
the cell surface in monocytes, macrophages and EBV
transformed B cells ([46–48] and our unpublished
results). Experimental evidence supports existence of
chaperones and co-chaperones such as Hsp90, Hsc70 on
the lysosomal membrane participating in lysosomal
proteolytic pathways such as chaperone-mediated
autophagy [49, 50]. Thus, it has been proposed that
cytosolic chaperones can enter the lysosomal lumen. It
seems likely that cytosolic proteins such as Hsp90 and
associated ligands might access endolysosomal com-
partments either during antigen internalization and/or
by autophagy. Another possibility is a potential role of
Hsp90 in sorting of peptide-MHCII complexes to MHCII-
rich multivesicular compartments in association with
accessory cytosolic signaling proteins. We are currently
investigating these possibilities.
Analysis of the presentation phenotype in activated
macrophage APC reveals that IFN-c activation enhances
MHCII-restricted presentation of both endogenous as
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well as exogenous antigens. This is unrelated to any
direct effects of IFN-c on Hsp90 induction, since we find
no changes in Hsp90 expression in activated APC (data
not shown and [31]). However, the presentation of
endogenous processing-derived EapL versus exogenous
OVA presentation by IFN-c-activated macrophage APC
exhibits a difference in sensitivity to geldanamycin. This
is not observed in the case of LPS-mediated APC
activation. The role for Hsp90 function in the MHCII-
mediated presentation pathway thus seems to have two
components. Our data present an essential Hsp90
function in presentation of peptides derived from
endogenous antigen sources, irrespective of the APC
activation status. The requirement for Hsp90 function in
the presentation of exogenous antigen reveals an
apparent dichotomy in that a component of the pathway
can be bypassed by IFN-c-induced APC activation
(Fig. 6). IFN-c-induced differential regulation of
endolysosomal activity is known to cause a shift in
the outcome of processing events [39–41] that could be
both quantitative and qualitative in terms of parameters
such as extensions flanking the core peptide or
conformational alterations. Such ligands may be pre-
sented in an Hsp90-independent manner. It is also
possible that the loading complex is differentially
modified by IFN-c to render exogenous presentation
relatively Hsp90 independent.
Taken together, our results provide evidence for
intricate associations of the major cellular chaperone,
Hsp90, with MHCII-restricted antigen presentation
pathways and uncover a novel role for Hsp90 as a
functional component in modulation of immune
responses.
Materials and methods
Mice
The mouse strains used, C57BL/6 (H-2b) and B10.A(3R)(H-
2i3), were bred in the small animal facility of the National
Institute of Immunology (New Delhi, India) and used at
8–10 weeks of age. All experiments were performed with the
approval of the Institutional Animal Ethics Committee.
Reagents
OVA (Sigma, St. Louis, MO) was dialyzed extensively against
PBS, to remove small degradation products. All inhibitors such
as geldanamycin, cytochalasin B and concanamycin A were
obtained from Sigma. Geldanamycin was reconstituted in
DMSO and used at a final concentration of 7.5 lM in the assays
shown. Cytochalasin B was used at a final concentration of
30 lM [32] and concanamycin A at 50–100 nM [33]. The
concentration of inhibitors for use in assays was determined by
titrations and earlier reports. Peptides corresponding to I-Ea
Figure 6. Model for the role of Hsp 90 in MHCII-restricted antigen presentation pathways in resting versus activated APC.
Endogenous/cytosolic antigen presentation is reliant on Hsp90 function, irrespective of the activation status of the APC. IFN-c-
mediated activation of APC (shaded region) renders the ability to bypass this essential requirement of Hsp90 function in the
exogenous antigen presentation (see text for details).
Deepa Rajagopal et al. Eur. J. Immunol. 2006. 36: 828–841838
f 2006 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji.de
(52-68), EapL and I-Ea (52-66), EapS were synthesized and
purified as described elsewhere [51].
Cell lines
T cell lines used were the MHCI (H-2Kb)-restricted T cell line
B3Z specific for the OVA-derived peptide, SIINFEKL, theMHCII
(H2-Ab)-restricted OVA-specific T cell hybridoma, 13.8 [18],
and the I-Ab restricted I-Ea (56–72) peptide (Eap)-specific T
cell hybridoma 1H3.1, which recognizes both endogenous and
exogenous forms of Eap [18]. The H-2b APC lines used were a B
cell line, LB27.4, and a monocytic line, BMC-2. The mA) used
were anti-H2-Db, Kb mAb Y-3, and the anti-H2-Ab mAb Y-3P.
Cytosolic antigen delivery by osmotic lysis of
pinosomes
Loading of proteins into the cytosol was done using osmotic
lysis of pinosomes as described [18, 30]. Briefly, APC were
incubated in 1 mL hypertonic serum-free Dulbecco's modified
essential medium (DMEM) containing 0.5 M sucrose, 10%
polyethylene glycol (PEG) 1000, 10 mM HEPES and the
antigen (protein at 10 mg/mL and peptide at 3 lg/mL) for
10 min at 37C. The volume was then made up to 10 mL, with
hypotonic DMEM (60% DMEM), followed by an additional
incubation for 2 min and washing in isotonic, serum-free
medium. Exogenous loading of antigen was done similarly
using isotonic medium for all steps. Cells were then incubated
at 37C for 3 h to allow antigen processing prior to being fixed
with 0.5% paraformaldehyde and used as APC for T cell
stimulation assays.
Antigen-presentation assays
Peritoneal exudates-derived plastic-adherent cells from mice
administered thioglycollate broth i.p. were used as macro-
phage APC. Resting macrophage APC were isolated by plastic
adherence from PBS washes of normal mouse peritoneal
cavity. The H-2b APC B cell line, LB27.4, and the monocytic
line, BMC-2, were also used as APC where indicated. APC were
pre-incubated for 1 h with 7.5 lM geldanamycin. The drug
was dissolved in DMSO as a stock solution and used at a final
maximal DMSO concentration of 0.1%. For inhibition of
endogenous antigen presentation APC were incubated over-
night with 5 lM geldanamycin. Cells were washed and loaded
with antigen either exogenously or cytosolically as described.
Fixed APC were titrated starting from 3  105 cells/well, in a
total culture volume of 200 lL/well DMEM with 10% FCS
(Biological Industries, Rehovot, Israel), antibiotics, L-gluta-
mine and 0.05 mM 2-ME in 96-well flat-bottom plates (Nunc,
USA). Responder T cell lines were added at 1  105 cells/well
and the plates were incubated for 24–36 h prior to analysis for
IL-2.
For stimulation assays of the 1H3.1 T cell line, IL-2 levels in
the culture supernatant were measured using commercial
enzyme immunoassay systems for IL-2, according to the
manufacturer's instructions (R& D Systems, Minneapolis,
USA). Both the B3Z and 13.8 T cell lines carry the lacZ gene
under a regulatory element from the IL-2 promoter [52]. Thus,
for activation of both 13.8 and B3Z, b-galactosidase production
was quantitated by a lacZ assay as detailed elsewhere [53].
Briefly, intracellular production of b-galactosidase was
detected following 24–36 h of culture using a substrate
solution containing the chromogenic substrate, chlorophenol
red-b-D-galactopyranoside (CPRG; Roche Diagnostics, Man-
nheim, Germany) in PBS, pH 7.4, containing 0.125% NP-40,
100 mM 2-ME, 9 mM MgCl2. Activation was monitored by
measuring absorbance at 570 nm.
Retrovirus-mediated gene transfer
A cDNA encoding human Hsp90 [31] cloned at the XhoI site of
the retroviral vector pMSCV-puro (Clontech, San Jose, CA)
was a kind gift from Dr. H. Udono (Department of Molecular
Medicine, Nagasaki University School of Medicine, Nagasaki,
Japan). The construct was transfected into the packaging cell
line, PT67, using Fugene 6 (Roche Molecular Biochemicals)
according to the manufacturer's instructions. Cells were
subjected to selection at 5 lg/mL of puromycin 24 h post-
transfection. The puromycin-resistant virus-producing PT67
cells were expanded and maintained in puromycin. For control
transductions, the eGFP gene was cloned in the BglII/NotI site
of the retroviral vector, pLNCX2 (Clontech, San Jose, CA) and
transductants selected for G418-resistance. Culture super-
natants from resistant clones were used as a source of virus for
transduction.
Retroviral transduction with Hsp90 virus-containing cul-
ture supernatants for both LB 27.4 and BMC-2 was carried out
in the presence of 6 lg/mL of polybrene, and cells were
subjected to puromycin selection 24 h post-transduction.
Stable clones identified following 2–3 weeks of culture were
maintained in the presence of puromycin. Similar transduc-
tions were also performed with eGFP-bearing retrovirus and
transductants similarly subjected to G418 selection. Prior to
use in antigen-presentation assays, cells were washed
extensively, cultured overnight in the absence of selection
and subsequently used as APC for presentation to T cells. For
flow cytometric analysis, the cells from selection cultures were
similarly washed and stained as outlined below.
Flow cytometry
APC were incubated with mAb culture supernatants for 1 h on
ice, followed by washes in cold staining buffer (PBS containing
0.5% BSA with 0.01% sodium azide). The secondary Ab used
was PE-conjugated goat anti-mouse Fc-specific, IgG F(ab)2 (BD
PharMingen, San Jose, CA). Flow cytometric data were
collected on a BD LSR flow cytometer (BD) and analyzed
with FlowJo software (Treestar, San Jose, CA). For staining
Hsp90, a mouse mAb raised against the C-terminal (586–732)
peptide of human Hsp90 and reactive against both mouse and
human Hsp90 (BD PharMingen, CA) was used. For permea-
bilization, cells were fixed and permeabilized with permea-
bilization buffer (BD Biosciences) for 15 min on ice and
washed extensively in Perm Wash buffer (BD Biosciences)
according to the manufacturer's instructions. Incubation with
primary and secondary antibodies was subsequently carried
out in Perm Wash buffer and as described above.
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SDS-PAGE and Western blot analyses of MHCII dimers
Whole-cell lysates of variously treated APC were made after
washing the cells once in ice-cold PBS. The cell pellets were
resuspended at 4C in 2-ME-free lysis buffer (1% NP-40, 1 mM
EDTA, 150 mM NaCl, 20 mM Tris.Cl, pH: 8.0, 1 mM MgCl2
containing 10 lg/mL leupeptin and aprotinin). Cell lysates
from an equivalent of one million cells each were resolved on
10% SDS-PAGE and transferred to nitrocellulose membranes
for Western blot analysis. Membranes were incubated with
antibody containing culture supernatant overnight at 4C.
After six washes at room temperature, horseradish peroxidase
(HRP)-labeled goat-anti-mouse IgG was added for 1 h at room
temperature. The membranes were again washed and
developed using di-aminobenzidine/hydrogen peroxide,
DAB/H2O2-containing substrate solution. For detecting actin,
rabbit polyclonal anti-actin antibody (Santa Cruz Biotech,
Santa Cruz, CA) followed by HRP-conjugated donkey-anti-
rabbit-IgGwas used. Hsp90was detected using themousemAb
mentioned above.
IFN-c and LPS stimulation assays
In assays involving IFN-c stimulation, 72-h thioglycollate-
elicited peritoneal exudates cells (PEC) were harvested and
rested overnight. Rested adherent PEC were either treated
with IFN-c at 10 U/mL for 48 h or left untreated in complete
medium. In the last 24 h of incubation, geldanamycin was
added at a concentration of 5 lM. The cells were harvested,
washed and then pulsed with OVA in isotonic medium as
described above at a concentration of 3 mg/mL. The APC were
similarly incubated for a further period of 3 h to allow antigen
processing in the presence or absence of IFN-c and/or
geldanamycin. The Tcell stimulation assays were subsequently
set up as described earlier. LPS stimulation was similarly
performed with LPS at a concentration of 3 lg/mL.
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